OCUGEN INC. - COMMON STOCK

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

20 5 2024 07:00:52 提供 Nasdaq GlobeNewswire

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

15 5 2024 06:30:00 提供 Nasdaq GlobeNewswire

Ocugen Provides Business Update with First Quarter 2024 Financial Results

14 5 2024 08:00:25 提供 Nasdaq GlobeNewswire

Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

10 5 2024 16:05:06 提供 Nasdaq GlobeNewswire

Ocugen to Present at May 2024 Investor Conferences

10 5 2024 07:45:07 提供 Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

03 5 2024 07:30:05 提供 Nasdaq GlobeNewswire

Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress

02 5 2024 07:15:46 提供 Nasdaq GlobeNewswire

Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024

29 4 2024 06:45:00 提供 Nasdaq GlobeNewswire

UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

26 4 2024 09:05:24 提供 Nasdaq GlobeNewswire

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

26 4 2024 06:30:40 提供 Nasdaq GlobeNewswire

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy

19 4 2024 07:13:05 提供 Nasdaq GlobeNewswire

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets

12 4 2024 07:30:34 提供 Nasdaq GlobeNewswire

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

10 4 2024 07:02:26 提供 Nasdaq GlobeNewswire

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

08 4 2024 06:30:43 提供 Nasdaq GlobeNewswire

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

05 4 2024 07:02:21 提供 Nasdaq GlobeNewswire

Ocugen Provides Business Update with Certain Financials for the Year Ending 2023

02 4 2024 08:00:39 提供 Nasdaq GlobeNewswire

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease

01 4 2024 18:08:46 提供 Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023

01 4 2024 17:43:45 提供 Nasdaq GlobeNewswire

Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

18 3 2024 06:30:50 提供 Nasdaq GlobeNewswire

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

13 3 2024 08:00:54 提供 Nasdaq GlobeNewswire